Heart failure is a prevalent and life-limiting condition, and studies show it affects patients in the Middle East a decade earlier in comparison to Western countries
Dubai, United Arab Emirates: Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has launched a website called 'Heart Talks' for heart failure patients and their caregivers in the region. Available in Arabic and English, the website covers comprehensive disease-related information needed for those living with the condition empowering them to understand heart failure, seek medical help on time, and manage their condition better.
Heart failure is a severe condition affecting millions of people worldwide each year. In recent years, countries in the Middle East have seen an earlier onset of the disease and an increase in the prevalence of risk factors that develop heart failure, which include diabetes mellitus, obesity, and hypertension.[1] Middle Eastern countries are, therefore, in need of prevention and awareness programs to help counter the development of this potentially fatal condition.
Dr. Mohamed Magdy, Head of Department of Cardiac Electrophysiology at Al Qassimi Hospital said: “It makes a big difference in patient care when the patient and their caregivers have access to all the necessary information about their disease in one place. The newly launched website also focuses on ways to prevent heart failure, which is one of the most important things we currently focus on as physicians. To reduce the prevalence of the illness and make treatment options even more efficient, patients must be aware of risk factors and symptoms. That way, they will be able to promote a healthier outcome for themselves.”
As part of Boehringer Ingelheim’s dedication to supporting and serving areas of high unmet patient needs beyond the research and development of treatments, the website provides access to valuable resources dedicated to the risks, causes, and ways of preventing heart failure.
To visit the website and learn more about heart failure prevention methods and risk factors, click معلومات مهمة عن قصور القلب معلومات أساسية عن فشل القلب (boehringer-ingelheim.com)
-Ends-
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.
[1] https://pubmed.ncbi.nlm.nih.gov/23597300/
© Press Release 2022
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.